Health
Regeneron’s Antibody Combination Therapy Reduces COVID-19 Mortality Risk – BioPharm International
RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for…
Results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial have shown that Regenerons investigational antibody combination therapy reduces the mortality risk for hospitalized patients with severe COVID-19 whose immune response has not started…
Continue Reading
-
Noosa News21 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference
-
Business20 hours agoDicker Data rides the AI trend to double digit growth
-
Business23 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy
-
Noosa News21 hours agoBob Katter threatens Channel 9 journalist for asking question on family heritage